Switching from Losartan to Valsartan in Hypertension with Heart Failure
Yes, you can switch from losartan 100 mg daily to valsartan 160 mg daily, but this switch requires careful consideration of target dosing and may not represent optimal therapy for heart failure with reduced ejection fraction.
Key Considerations for the Switch
Dose Equivalency Issues
The proposed switch is not equivalent in terms of evidence-based target dosing for heart failure:
Losartan 100 mg daily is already at the maximum approved dose for hypertension but falls short of the optimal heart failure dose. The HEAAL trial demonstrated that losartan 150 mg daily (not the commonly prescribed 100 mg) is superior for heart failure outcomes, showing a 10% relative risk reduction in death or HF hospitalization 1.
Valsartan 160 mg daily is also suboptimal. The target dose proven effective in heart failure trials is 320 mg daily (160 mg twice daily) 2, 1. Studies show valsartan's antihypertensive effect increases predictably over the dose range of 20-320 mg, and 160 mg provides better efficacy than lower doses while maintaining tolerability comparable to placebo 3.
Evidence-Based Recommendations
For heart failure with reduced ejection fraction, both ARBs are acceptable but neither at your proposed doses:
- ARBs are recommended as alternatives to ACE inhibitors when patients are intolerant (Class I, Level A) 4, 5
- Both valsartan and candesartan have demonstrated mortality/morbidity benefits in heart failure trials 2, 1
- Losartan 50 mg daily failed to demonstrate non-inferiority to captopril in the OPTIMAAL trial, highlighting the importance of adequate dosing 1
Optimal Approach
Instead of a simple 1:1 switch, consider this algorithm:
If switching is necessary (e.g., cost, availability):
If staying with losartan:
Consider sacubitril/valsartan instead:
Critical Dosing Pitfalls
Common errors to avoid:
- Underdosing is prevalent: Less than 25% of patients reach target doses in clinical practice, yet higher doses provide greater benefits 7
- Once-daily valsartan for heart failure: While studied and found safe 9, the landmark trials used twice-daily dosing for heart failure 2, 1
- Confusing hypertension doses with heart failure doses: Valsartan 40-80 mg daily treats hypertension; heart failure requires 320 mg daily 7
Monitoring During Transition
When switching or uptitrating:
- Check blood pressure, serum creatinine, and potassium at 1-2 weeks after each dose change
- Do not discontinue for mild hypotension (SBP >90 mmHg) or modest creatinine increases (<30% rise) unless symptomatic 8
- Temporary dose reductions can often be restored to target doses (40% success rate in PARADIGM-HF) 7
- Adjust concomitant diuretics if needed rather than stopping the ARB 2
Bottom Line
The proposed switch from losartan 100 mg daily to valsartan 160 mg daily is feasible but represents suboptimal dosing for both drugs in heart failure. Target valsartan 160 mg twice daily (320 mg total) or losartan 150 mg daily for evidence-based heart failure management 2, 1. Better yet, evaluate eligibility for sacubitril/valsartan, which provides superior outcomes in HFrEF 5, 8.